{
  "docId": "019de073-79f3-7749-b6d9-2feecaaa4d92",
  "docSlug": "3bbd721bd246637706dab09d5c4f3165",
  "documentTitle": "Apexigen | Investor Presentation Deck | 27 slides",
  "authorId": "apexigen",
  "authorName": "Apexigen",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 9,
  "pageCount": 27,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "solution",
  "function": "present_solution",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide uses a comparative framework to position the drug as a superior alternative to existing checkpoint inhibitors.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-79f3-7749-b6d9-2feecaaa4d92/9",
  "deckHref": "/decks/019de073-79f3-7749-b6d9-2feecaaa4d92",
  "deckJsonHref": "/decks/019de073-79f3-7749-b6d9-2feecaaa4d92.json",
  "deckAnchorHref": "/decks/019de073-79f3-7749-b6d9-2feecaaa4d92#slide-9",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.15,
        "x": 0.83,
        "y": 0.32
      },
      "kind": "callout",
      "text": "BENEFITS OF TARGETING CD40: Both immunity arms: More powerful response, Upstream of T-cell activation: Enable T cell response, Modulates tumor microenvironment: Cold -> hot tumor",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a213c454-4d0f-4e99-baec-318e981932c4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.55,
        "x": 0.32,
        "y": 0.2
      },
      "kind": "diagram",
      "text": "Mechanism of action of Sotigalimab showing activation of innate and adaptive immune cells leading to tumoricidal effects.",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dbeecdf5-0d4c-4e4e-8bf2-70d3e763476b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.25,
        "x": 0.05,
        "y": 0.515
      },
      "kind": "list",
      "text": "Therapeutic index, Toxicity, Only effective in subset of patients, Adaptive but not innate immunity",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c91ef3d6-c8cb-49ed-997f-db3696ae142e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.65,
        "x": 0.04,
        "y": 0.04
      },
      "kind": "title",
      "text": "Targeting CD40: A Key Pathway in Stimulating Immune Response Against Cancer",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4bcf55e1-ae26-429f-9ad9-d408cb785291",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "before-after-framing",
      "slug": null,
      "matchId": "496565ec-304a-459d-860e-6ec5765188f9",
      "evidence": "Contrasts current checkpoint inhibitor challenges with the proposed solution's benefits.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 11,
      "from": 9,
      "beatId": "bfa88b56-3bff-4ff7-bf10-cf826d73f1e6",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "Slides 9-11 present Sotigalimab as a solution, including its design and differentiation from other CD40 agonists",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 11,
      "from": 9,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "5026d18e-139d-4879-9fd9-ca4f599102e8",
      "evidence": "The solution section presents Sotigalimab as a rationally designed and differentiated CD40 agonist",
      "position": 1,
      "objective": "Why is Sotigalimab a good solution?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}